Considering the inferior clinical outcomes of KRAS-mutant CRC tumors, we performed an integrative clustering analysis to better stratify patients for therapeutic interventions and provide a more precise assessment of phenotypic heterogeneity. This evidence concerns the gene KRAS and colorectal carcinoma.